<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of precocious puberty
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of precocious puberty
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of precocious puberty
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer Harrington, MBBS, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark R Palmert, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Snyder, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mitchell E Geffner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 09, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H23810861">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Precocious puberty is traditionally defined as the onset of secondary sexual development before the age of eight years in females and nine years in males. Because of trends towards earlier pubertal development, some healthy females will have breast or pubic hair development before this age, and extensive evaluation and treatment may not be required. If the evaluation leads to a diagnosis of progressive precocious puberty, treatment may be considered.
        </p>
        <p>
         The treatment of precocious puberty, which depends upon the underlying cause, will be discussed in this topic. The definition, etiology, and evaluation of precocious puberty are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23808232">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Precocious puberty can be classified based upon the underlying pathologic process.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central
         </strong>
         <strong>
          precocious puberty
         </strong>
         – Central precocious puberty (CPP, also known as gonadotropin-dependent precocious puberty or true precocious puberty) is caused by early maturation of the hypothalamic-pituitary-gonadal axis. It is characterized by sequential maturation of breasts and pubic hair in females, and of maturation of the testes, penis, and pubic hair in males. The sexual characteristics are appropriate for the child's sex (isosexual). CPP is idiopathic in 80 to 90 percent of cases in females, whereas intracranial lesions are detected in 20 to 75 percent of males with CPP (
         <a class="graphic graphic_table graphicRef52565" href="/z/d/graphic/52565.html" rel="external">
          table 1A
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Causes of central precocious puberty'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral precocity
         </strong>
         – Peripheral precocity (also known as gonadotropin-independent precocious puberty or peripheral precocious puberty) is caused by excess secretion of sex hormones (estrogens or androgens) derived either from the gonads or adrenal glands, exogenous sources of sex steroids, or ectopic production of gonadotropins from a germ cell tumor (eg, human chorionic gonadotropin [hCG]) (
         <a class="graphic graphic_table graphicRef59268" href="/z/d/graphic/59268.html" rel="external">
          table 1B
         </a>
         ). We use the term precocity instead of puberty because puberty implies activation of the hypothalamic-pituitary-gonadal axis, as occurs in CPP, whereas precocity refers only to the secondary sexual characteristics. Peripheral precocity is most commonly either isosexual (concordant with the child's sex), or contrasexual (with virilization of females and feminization of males), but can also present with both virilizing and feminizing features in rare cases. (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Causes of peripheral precocity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benign or nonprogressive pubertal variants
         </strong>
         – Benign pubertal variants include isolated breast development in females (premature thelarche) or isolated androgen-mediated sexual characteristics (such as pubic and/or axillary hair, acne, and apocrine odor) in males or females that result from early activation of the hypothalamic-pituitary-adrenal axis (premature adrenarche) (
         <a class="graphic graphic_table graphicRef72054" href="/z/d/graphic/72054.html" rel="external">
          table 1C
         </a>
         ). Both of these conditions can be a variant of normal puberty. However, repeat evaluations may be warranted in these children to be certain that the diagnosis is correct. (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Types of benign or nonprogressive pubertal variants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23808992">
         <span class="h1">
          TREATMENT FOR CENTRAL PRECOCIOUS PUBERTY
         </span>
         <span class="headingEndMark">
          —
         </span>
         When warranted, pubertal progression in central precocious puberty (CPP) can be treated by administration of a gonadotropin-releasing hormone (GnRH) agonist. GnRH agonists work by providing continuous stimulation to the pituitary gonadotrophs, instead of physiologic pulsatile stimulation from hypothalamic GnRH. Continuous stimulation leads to desensitization of the gonadotroph cells and suppression of gonadotropins, resulting in decreased sex steroid production [
         <a href="#rid1">
          1
         </a>
         ], a phenomenon referred to as pituitary-gonadal axis suppression. This treatment can be used for patients with idiopathic or neurogenic CPP [
         <a href="#rid2">
          2,3
         </a>
         ], or for secondary activation of CPP, which may occur in patients who initially present with peripheral precocity. However, not all patients with CPP require treatment, as outlined in the following section.
        </p>
        <p>
         When CPP is caused by an identifiable central nervous system (CNS) lesion (neurogenic CPP), therapy is also directed toward the underlying pathology when possible. Benign hypothalamic hamartomas are often left in situ and monitored neuroradiologically over time [
         <a href="#rid4">
          4
         </a>
         ], unless associated with significant generalized epileptic activity [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23809000">
         <span class="h2">
          Decision to treat
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision of whether to treat CPP with a GnRH agonist depends upon the child's age, the rate of pubertal progression (sexual maturation), height velocity, and the estimated adult height as determined from the rate of bone age advancement. Pubertal progression would be considered slow if there is no change in stage of breast, pubic hair, or genital development during six or more months of observation (
         <a class="graphic graphic_table graphicRef72017" href="/z/d/graphic/72017.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ]. Height velocity is considered accelerated if it is more than 6 cm per year. The relationship between pubertal stages and height velocity in normally developing children is outlined in the figure (
         <a class="graphic graphic_figure graphicRef52047 graphicRef72046" href="/z/d/graphic/52047.html" rel="external">
          figure 1A-B
         </a>
         ) and discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5849.html" rel="external">
          "Normal puberty", section on 'Pubertal changes'
         </a>
         .)
        </p>
        <p>
         Clinical decision-making related to height preservation is guided by the following considerations (decision-making related to psychosocial concerns is described below (see
         <a class="local">
          'Goals of treatment'
         </a>
         below)):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age
         </strong>
         – Children with CPP who present at a younger age and have a rapid progression of maturation benefit the most from therapy because they have early epiphyseal fusion and reduced adult height if they are not treated [
         <a href="#rid7">
          7,8
         </a>
         ]. In contrast, children who present close to the age of normal puberty or who have a very slowly progressive variant of precocious puberty may not require therapy, particularly if their adult height without treatment is concordant with their midparental height range [
         <a href="#rid9">
          9-12
         </a>
         ]. Treatment decisions should be individualized, and initiation of GnRH agonist therapy may be indicated for some children with onset of precocious puberty closer to the normal range [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For females with onset of CPP before the age of six years, GnRH agonist treatment results in an average gain in adult height of 9 to 10 cm, whereas for those with onset of CPP between six and eight years, treatment results in an average gain in adult height of 4 to 7 cm [
         <a href="#rid8">
          8,13,14
         </a>
         ]. The degree of bone age advancement prior to treatment initiation can, however, attenuate this height gain [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For males, fewer data are available. One study estimated that GnRH treatment beginning at an average age of 7.6 years resulted in a mean height gain of 6.2±8.7 cm [
         <a href="#rid15">
          15
         </a>
         ]. Two expert panels concluded that it is reasonable to consider GnRH agonist treatment for males with progressive CPP if they present before nine years of age [
         <a href="#rid7">
          7,8
         </a>
         ]. As in females, the height gain conferred by GnRH agonist therapy is less robust for patients who have more advanced bone age at the initiation of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rate of maturation
         </strong>
         <strong>
          (pubertal progression)
         </strong>
         – If precocious puberty is slowly progressive, it is unlikely to compromise adult height and in that instance we do not suggest therapy [
         <a href="#rid8">
          8,16
         </a>
         ]. In a study of 16 such children who were followed for 12 years without treatment, all reached normal adult height [
         <a href="#rid9">
          9
         </a>
         ]. Despite the early onset of breast development in this group, menarche occurred at a normal age (average age 11 years). Similarly, in a group of 35 males with slowly progressive puberty (defined as progression from sexual maturity rating [Tanner] stage 2 to 3 over more than 18 months) who were not treated, adult height was within the range of their target height [
         <a href="#rid11">
          11
         </a>
         ]. Clinical experience has shown that many cases of precocious puberty, particularly in females with onset after six years of age, will be slowly progressive.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estimated adult height
         </strong>
         – If the predicted adult height approximates the mid-parental height, therapy is probably not needed and a conservative approach is therefore warranted [
         <a href="#rid17">
          17
         </a>
         ]. A variety of methods can be used to predict adult height. A common method developed by Bayley and Pinneau employs a table to predict adult height based upon the child's bone age and chronologic age. Height prediction methods have, however, often been found to overpredict the adult height in children with precocious puberty.
        </p>
        <p>
        </p>
        <p>
         Based upon the data described above, we suggest initiation of GnRH agonist therapy for a female presenting with CPP before the age of six with progressive breast and pubic hair development, advanced bone age, and accelerated height velocity. Conversely, in an individual with somewhat later onset of CPP and/or historically slow progression of pubertal development without a substantial increase in height velocity or advancement of bone age, we suggest monitoring without treatment for three to six months to establish the pace of the pubertal progression before making treatment decisions [
         <a href="#rid7">
          7,8
         </a>
         ]. For males, we treat all those presenting with CPP before the age of nine years, unless there is evidence of slow pubertal progression and/or acceptable height prediction, in which case, we monitor clinically to assess the pace of pubertal progression before making treatment decisions [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18658176">
         <span class="h2">
          Goals of treatment
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A primary goal of treatment for CPP is to allow a child to grow to a normal adult height. Therefore, as noted above, the decision to treat should include analysis of the predicted height benefit from treatment. (See
         <a class="local">
          'Decision to treat'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another goal of therapy is to relieve psychosocial stress. Parents are often concerned about the prospect of early menses, which might be distressing to a young girl. However, the data regarding the psychosocial impact of CPP are limited. A study of 19 females with CPP prior to treatment initiation found no difference in psychological distress as compared with females with normal puberty [
         <a href="#rid18">
          18
         </a>
         ]. A study of 10 females with CPP demonstrated reduced stress levels following one year of GnRHa therapy [
         <a href="#rid19">
          19
         </a>
         ]. However, another study of 36 females with CPP demonstrated improvement in psychological scores irrespective of GnRHa treatment [
         <a href="#rid20">
          20
         </a>
         ]. Because of scant data in this area, treatment primarily to address perceived psychosocial consequences of precocious puberty should be approached with caution [
         <a href="#rid7">
          7
         </a>
         ]. This caution is especially true for females with pubertal onset at the edge of the normal range, whereas treatment of a very young child may be warranted even in the absence of strong data. In females with developmental disabilities where the goal of treatment may be suppression of menses rather than height preservation, alternate treatment approaches such as intramuscular (depot) medroxyprogesterone, continuous oral contraceptive pills, or intrauterine devices can be considered [
         <a href="#rid16">
          16,21
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/5423.html" rel="external">
          "Hormonal contraception for menstrual suppression"
         </a>
         ). It is important to take a family-centered approach to the decision to initiate therapy for CPP by ensuring that the caregivers are fully informed about the pros and cons of the therapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H568107578">
         <span class="h2">
          GnRH agonist therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with CPP, GnRH agonist administration results in an initial transient stimulation of gonadotropin secretion from the pituitary, followed by a complete, but reversible, suppression of the pituitary-gonadal axis. The initial stimulation of gonadotropins is the basis for using these drugs in a stimulation test to distinguish CPP from peripheral precocity or benign pubertal variants. (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Serum LH concentrations after GnRH agonist stimulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23809021">
         <span class="h3">
          Formulations and dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sustained-release formulations of several GnRH agonists have been developed: depot preparations for monthly, three-, or six-monthly dosing and a subcutaneous implant that is surgically inserted every 12 months (
         <a class="graphic graphic_table graphicRef72979" href="/z/d/graphic/72979.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ]. The choice of GnRH agonist formulation depends on patient and clinician preference and local regulatory approvals [
         <a href="#rid8">
          8
         </a>
         ]. These preparations have not been directly compared in randomized trials but appear to be similarly effective in suppressing the pituitary-gonadal axis [
         <a href="#rid22">
          22-32
         </a>
         ].
        </p>
        <p>
         Short-acting GnRH agonist formulations are also available, including daily subcutaneous injections and multiple daily dosing intranasal sprays (
         <a class="drug drug_general" data-topicid="9673" href="/z/d/drug information/9673.html" rel="external">
          nafarelin
         </a>
         acetate). Depot preparations are preferable because of improved compliance and thus better pituitary-gonadal axis suppression [
         <a href="#rid33">
          33
         </a>
         ]. However, in certain clinical situations, such as the development of sterile abscesses with depot GnRH agonist therapy, these daily preparations can be used as an alternative.
        </p>
        <p>
         The different GnRH agonist preparations and typical starting doses used in various countries are outlined in the table (
         <a class="graphic graphic_table graphicRef72979" href="/z/d/graphic/72979.html" rel="external">
          table 3
         </a>
         ). Our typical approach to GnRH agonist depot dosing is described below. (See
         <a class="local">
          'Our approach'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H23809028">
         <span class="h3">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         After GnRH agonist therapy has begun, follow-up monitoring should be performed to ensure that the goals of GnRH agonist therapy are being achieved (eg, suppression of the pituitary-gonadal axis, slowing of development of secondary sexual characteristics, slowing of bone age advancement, and, ultimately, increases in predicted adult height). If treatment is effective, further breast and testicular development and menses should cease and height velocity and rate of bone age advancement should decline. Therefore, routine monitoring should include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation of pubertal development and growth every three to six months. Effective GnRH agonist therapy should result in a decrease in height velocity, cessation of menses, and arrest pubertal progression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Periodic bone age measurements (eg, every 6 to 12 months), looking for a reduction in the bone age advancement [
         <a href="#rid2">
          2,7
         </a>
         ]. Once this has been documented, bone age measurements can be performed less frequently (eg, every one to two years).
        </p>
        <p>
        </p>
        <p>
         In our practice, we do not routinely monitor serum LH and sex steroid concentrations during GnRH agonist therapy, because we believe there are insufficient data to demonstrate that using such measurements to adjust therapy improves adult height outcomes [
         <a href="#rid8">
          8
         </a>
         ]. However, we recognize that this is a controversial topic and that other clinicians prefer to monitor biochemically for evidence of pituitary-gonadal axis suppression and adjust treatment accordingly. Such measurements include basal LH and sex steroid concentrations (estradiol in females and testosterone in males) or stimulated LH and sex steroid levels (after GnRH or a GnRH agonist administration). Native GnRH is not available in the United States; therefore, some clinicians use the next scheduled GnRH agonist injection for the stimulated LH sample.
        </p>
        <p>
         Regardless of whether biochemical monitoring is performed, ongoing careful clinical assessment is paramount. If there is evidence of ongoing pubertal progression once therapy has begun, then the above biochemical measurements may be used to assess whether there is complete suppression of the pituitary-gonadal axis [
         <a href="#rid34">
          34,35
         </a>
         ]. If this testing shows incomplete suppression of the pituitary-gonadal axis, the GnRH agonist dose should be increased or the interval between doses decreased. (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Basal serum luteinizing hormone'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Serum LH concentrations after GnRH agonist stimulation'
         </a>
         .)
        </p>
        <p>
         Within the first weeks after the initial dose of the GnRH agonist, vaginal bleeding may occur due to estradiol withdrawal because the treatment initially stimulates estradiol production before suppressing the pituitary-gonadal axis. If vaginal bleeding occurs later in the course of treatment, this either indicates lack of suppression of the pituitary-gonadal axis or an alternative diagnosis to CPP (eg, a cause of peripheral precocity). Pubic hair stage may advance due to adrenarche despite effective treatment with GnRH agonists because these agents have no effect on adrenal androgen production [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H436360027">
         <span class="h3">
          Treatment duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of GnRH agonist therapy should be long enough to optimize final adult height, yet still allow progression of pubertal characteristics at an age that is concurrent with the individual's peers. When GnRH agonist therapy with monthly depot preparations is stopped, normal puberty returns, on average, within 12 to 18 months.
        </p>
        <p>
         In one study, menarche occurred 17.5±11.2 months after the last injection of GnRH. It was somewhat earlier in females who had menstruated prior to GnRH treatment (mean age of resuming menses 12.7±1.3 years, approximately nine months after the last GnRH injection), compared with those who had not previously menstruated (mean age of menarche 13.1±1.5 years, approximately 19 months after the last GnRH injection) [
         <a href="#rid37">
          37
         </a>
         ]. In males, the interval between the last injection of GnRH and achievement of adult testosterone levels was 11±10.9 months. If
         <a class="drug drug_pediatric" data-topicid="87619" href="/z/d/drug information/87619.html" rel="external">
          histrelin
         </a>
         implants are used, reports suggest that the average length of time between removal of the implant and resumption of menses is approximately 12 months, with wide variability [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H65751955">
         <span class="h3">
          Safety
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Short-term
         </strong>
         – Potential adverse effects of GnRH agonist therapy include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Localized adverse effects of the one-, three-, and six-monthly depot injections include transient pain and local reactions at the injection sites, and, although uncommon, sterile abscess formation [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For
         <a class="drug drug_pediatric" data-topicid="87619" href="/z/d/drug information/87619.html" rel="external">
          histrelin
         </a>
         implants, the extraction procedure can be complicated by breakage of the implant in 15 to 39 percent of cases, with a higher likelihood of breakage if the implant is left in for two years rather than shorter periods of time [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Systemic hypersensitivity reactions have been reported in &lt;4 percent of patients [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pseudotumor cerebri (idiopathic intracranial hypertension) has been described in a few case reports [
         <a href="#rid42">
          42-44
         </a>
         ]. This appears to be rare, but patients should be monitored for suggestive symptoms, including headache, papilledema, or blurred vison.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A risk of prolonged QT interval has been raised because this complication has been reported for GnRH agonist therapy in a small number of men with prostate cancer. As a result, the Pediatric Endocrine Society recommended that risk factors for prolonged QT interval be identified prior to initiating GnRH agonist therapy, including concomitant medications known to prolong the QT interval or a family history of long QT syndrome, congenital heart disease, arrhythmia, or sudden death [
         <a href="#rid45">
          45,46
         </a>
         ]. Patients with these risk factors should be monitored by electrocardiogram prior to commencement of GnRH agonist therapy and again when the GnRH agonist dose has reached steady state. The frequency of this complication and whether it occurs in children/youth have yet to be determined.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term
         </strong>
         – No long-term adverse effects of GnRH agonist therapy have been demonstrated:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment with GnRH agonists appears to have no significant long-term effects on the pituitary-gonadal axis [
         <a href="#rid47">
          47
         </a>
         ]. In long-term follow-up of females who were treated with GnRH agonists, the rate of regular menstrual cycles and fertility was not different from the general population [
         <a href="#rid48">
          48-50
         </a>
         ]. For males, small studies show normal gonadal function after completing treatment with GnRH agonists [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although earlier pubertal development is associated with obesity, long-term treatment with GnRH agonists does not appear to cause or exacerbate obesity in adolescence or adulthood [
         <a href="#rid8">
          8,52,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         While bone mineral density may slightly decrease during GnRH agonist administration, these changes are not sustained, with preservation of peak bone mass accrual after discontinuation of therapy [
         <a href="#rid54">
          54,55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Overall, there is no clear evidence that GnRH agonist treatment increases the risk for polycystic ovary syndrome [
         <a href="#rid7">
          7,8,47
         </a>
         ]. The reported incidence of polycystic ovary syndrome in females with CPP is variable, with some series reporting up to a 32 percent incidence [
         <a href="#rid56">
          56
         </a>
         ], while others report rates of 0 to 12 percent, an incidence not different from the general population [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23809042">
         <span class="h3">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         After a progressive form of CPP has been identified and discussion with the family has resulted in a decision to treat, the choice of GnRH agonist formulation depends upon patient and clinician preference, insurance company coverage, and local regulatory approvals. Families should be counseled that some vaginal bleeding may occur after the initiation of GnRH agonist therapy due to transient stimulation of the pituitary-gonadal axis with the first dose. Similarly, males can experience a transient increase in erections.
        </p>
        <p>
         A variety of dosing schemes are effective. Starting doses used in Europe tend to be somewhat lower than those in the United States (as outlined in the table (
         <a class="graphic graphic_table graphicRef72979" href="/z/d/graphic/72979.html" rel="external">
          table 3
         </a>
         )); additionally, other products are available worldwide but not in the United States. Our approach includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Given the GnRH agonist preparations available to us, we typically use the three-month preparation of
         <a class="drug drug_pediatric" data-topicid="12545" href="/z/d/drug information/12545.html" rel="external">
          leuprolide
         </a>
         depot (Lupron Depot PED [three month]) at a starting dose of 11.25 mg. If puberty is not adequately suppressed, we decrease the interval between doses or titrate up the dose.
         <a class="drug drug_pediatric" data-topicid="120073" href="/z/d/drug information/120073.html" rel="external">
          Triptorelin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="87619" href="/z/d/drug information/87619.html" rel="external">
          histrelin
         </a>
         can be substituted for Lupron Depot PED where available if preferred.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For young children (under two years of age) or children with hypothalamic hamartomas (groups in which control of puberty may be more difficult), we often instead use
         <a class="drug drug_pediatric" data-topicid="12545" href="/z/d/drug information/12545.html" rel="external">
          leuprolide
         </a>
         depot (Lupron Depot PED [one month]), given intramuscularly every 28 days, with a starting dose of 7.5 mg. After suppression is achieved, we typically switch to three-monthly preparations if desired by the family. (See
         <a class="local">
          'Formulations and dosing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We monitor the response to the GnRH agonist by assessing pubertal development and height velocity every three to six months and bone age initially every 6 to 12 months. If pubertal progression is not suppressed, the dose of GnRH agonist is adjusted upward or the interval between doses is shortened. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We generally continue treatment until approximately age 11 years in females and age 12 years in males. The decision of when to discontinue GnRH agonist therapy is individualized [
         <a href="#rid13">
          13
         </a>
         ]; contributing factors include the age of the child, bone age and height age, predicted height, and desire to have pubertal progression concurrent with their peers. (See
         <a class="local">
          'Treatment duration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23809049">
         <span class="h1">
          TREATMENT FOR PERIPHERAL PRECOCITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peripheral sexual precocity (also referred to as gonadotropin-independent precocious puberty or peripheral precocious puberty) is caused by excess secretion of sex hormones (estrogens or androgens) derived from the gonads, adrenal glands, or exogenous sources or driven by ectopic production of gonadotropin from a germ cell tumor (eg, human chorionic gonadotropin [hCG]) (
         <a class="graphic graphic_table graphicRef59268" href="/z/d/graphic/59268.html" rel="external">
          table 1B
         </a>
         ). The causes and evaluation of peripheral precocity are discussed in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Causes of peripheral precocity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7811799">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peripheral precocity does not respond to gonadotropin-releasing hormone (GnRH) agonist therapy. Instead, treatment is directed at blocking the production of and/or response to the sex steroids, depending on the cause:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumors of the testis, adrenal gland, or ovary – These are treated by surgery. hCG-secreting tumors may also require radiation therapy and chemotherapy, depending upon the site and histologic type.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Functioning follicular cysts of the ovary – These develop and regress spontaneously, so conservative management without surgery is generally appropriate [
         <a href="#rid57">
          57-59
         </a>
         ]. Patients should be followed clinically to document regression in the clinical signs of precocity. If there is no clinical evidence of pubertal regression, ultrasonography of the ovaries should be performed. (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Ovarian cysts'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exposure to exogenous sex steroids – The source should be identified and removed. After removal, the pubertal changes are likely to regress. (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Exogenous sex steroids and endocrine-disrupting chemicals'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Defects in adrenal steroidogenesis, such as classic congenital adrenal hyperplasia – These should be treated with glucocorticoids. (See
         <a class="medical medical_review" href="/z/d/html/149.html" rel="external">
          "Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Adrenal pathology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         McCune-Albright syndrome and familial male-limited precocious puberty – These disorders require a different approach because they are caused by mutations resulting in overstimulation of the tissues that produce sex steroids. (See
         <a class="local">
          'McCune-Albright syndrome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Children with peripheral precocity with exposure to high serum sex steroid levels are at risk for developing secondary central precocious puberty (CPP) once the cause of peripheral precocity has been treated. Clinical monitoring for signs of progressive breast or testicular development is therefore important after treating a child with peripheral precocity. Addition of a GnRH agonist may be warranted if CPP has developed. (See
         <a class="local">
          'GnRH agonist therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H23809056">
         <span class="h2">
          McCune-Albright syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         McCune-Albright syndrome (MAS;
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F174800&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2FMJLpJUTBcJsVzhaWWgcSmNrdjF44VUbbLG8%2BNKIsK4&amp;TOPIC_ID=16318" target="_blank">
          MIM #174800
         </a>
         ) is a rare genetic disorder defined as the triad of peripheral sexual precocity, café-au-lait skin pigmentation, and fibrous dysplasia of bone. It is caused by a somatic (postzygotic) mutation of the gene encoding the alpha subunit of the Gs protein that results in constitutive activation of adenylyl cyclase in affected tissues [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         Affected females tend to form recurrent ovarian cysts, resulting in estradiol secretion and intermittent vaginal bleeding. The ovarian enlargement is sometimes mistaken for an ovarian tumor, leading to unnecessary oophorectomy [
         <a href="#rid61">
          61
         </a>
         ]. Affected males produce excess testosterone, but they are less likely to develop sexual precocity. Testicular abnormalities on ultrasound that most likely represent Leydig cell hyperplasia are common [
         <a href="#rid62">
          62
         </a>
         ]. To preserve fertility, children with MAS should be treated with drugs that inhibit gonadal steroidogenesis or gonadal steroid action, rather than surgery.
        </p>
        <p>
         The clinical presentation and diagnosis of MAS is discussed separately (see
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'McCune-Albright syndrome'
         </a>
         ). More detailed information, including evaluation and management of associated skeletal abnormalities, renal phosphate wasting, and other endocrine abnormalities, is described in a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fojrd.biomedcentral.com%2Farticles%2F10.1186%2Fs13023-019-1102-9&amp;token=OpQOIvdvUJfCTjO1iOdBUQpMrdeJgn%2FR5UMqjFjdqIwN0U%2FtMdIDQe51QXNKBNxcquRqGe66SMKVdOJTpIYgkCqoe8SURwoFVIuh4WLuXqg%3D&amp;TOPIC_ID=16318" target="_blank">
          guideline from an international consortium
         </a>
         [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H568109635">
         <span class="h3">
          Females
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 85 percent of females with MAS develop precocious puberty [
         <a href="#rid60">
          60
         </a>
         ]. One goal of treatment is to reduce the potential for compromised adult height due to early epiphyseal fusion from sustained estrogen exposure in young females. A second goal is to reduce the psychological impact of recurrent vaginal bleeding [
         <a href="#rid64">
          64
         </a>
         ]. Treatment for females with MAS has included strategies to block estrogen biosynthesis with aromatase inhibitors or block estrogen action (
         <a class="graphic graphic_figure graphicRef62460" href="/z/d/graphic/62460.html" rel="external">
          figure 2
         </a>
         ). While there is no consensus on the optimum treatment, we use an aromatase inhibitor (
         <a class="drug drug_pediatric" data-topicid="94329" href="/z/d/drug information/94329.html" rel="external">
          letrozole
         </a>
         ); this practice is based upon the limited clinical experience outlined below:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aromatase inhibitors – Treatment with
         <a class="drug drug_pediatric" data-topicid="94329" href="/z/d/drug information/94329.html" rel="external">
          letrozole
         </a>
         has become one of the commonly used therapeutic approaches for females with MAS [
         <a href="#rid63">
          63
         </a>
         ]. In a pilot study of nine females treated with letrozole, the episodes of vaginal bleeding either ceased or decreased and there was a decrease in bone age advancement [
         <a href="#rid65">
          65
         </a>
         ]. One patient, however, developed a large ovarian cyst with clinical symptoms suggestive of torsion. A follow-up study of 28 females treated with letrozole for a mean of 4.1 years demonstrated further improvement in predicted adult height, without any further cases of ovarian torsion [
         <a href="#rid66">
          66
         </a>
         ]. More data on the long-term safety and impact of letrozole on adult height from larger cohorts of patients are still needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical experience suggests that other aromatase inhibitors are less effective. Testolactone, a first-generation aromatase inhibitor, is partially effective for reducing the recurrence of ovarian cysts and slowing pubertal progression [
         <a href="#rid67">
          67
         </a>
         ], but there is a loss of efficacy over time [
         <a href="#rid68">
          68
         </a>
         ]. For reasons that are not clear, the newer-generation aromatase inhibitors, fadrozole and
         <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">
          anastrozole
         </a>
         , are largely ineffective for long-term treatment [
         <a href="#rid69">
          69-71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blockers of estrogen action – Drugs that block estrogen action appear to have some efficacy, but their clinical role remains unclear because evidence is limited to small case series. Treatment with
         <a class="drug drug_pediatric" data-topicid="87811" href="/z/d/drug information/87811.html" rel="external">
          tamoxifen
         </a>
         , a selective estrogen receptor modulator (SERM), has been shown to decrease the vaginal bleeding episodes and slow the rate of bone age advancement in a study of 28 females [
         <a href="#rid72">
          72
         </a>
         ]. However, uterine and ovarian volumes increased by the end of the study, raising concerns about long-term safety. In a retrospective study of eight females treated with tamoxifen, the predicted adult height improved during treatment [
         <a href="#rid73">
          73
         </a>
         ]. However, in the four females who had completed their growth during the follow-up period, the gain in adult height was modest (average of 4.3 cm).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a one-year open-label trial of
         <a class="drug drug_pediatric" data-topicid="87808" href="/z/d/drug information/87808.html" rel="external">
          fulvestrant
         </a>
         , a pure estrogen receptor antagonist, most subjects who had vaginal bleeding at baseline experienced either a substantial reduction or cessation of bleeding, and rates of bone age advancement decreased significantly [
         <a href="#rid74">
          74
         </a>
         ]. These results are promising but long-term safety or efficacy outcomes for fulvestrant treatment of MAS are not yet available.
        </p>
        <p>
        </p>
        <p>
         A few patients with MAS will develop a component of central precocious puberty (CPP). This is probably caused by prolonged fluctuating exposure to elevated levels of sex steroids and is most often found in patients with advanced bone age. Such patients may respond to adjuvant treatment with a GnRH agonist, as do other children with CPP [
         <a href="#rid75">
          75
         </a>
         ]. (See
         <a class="local">
          'GnRH agonist therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H568109641">
         <span class="h3">
          Males
         </span>
         <span class="headingEndMark">
          —
         </span>
         MAS is less common in males than females [
         <a href="#rid76">
          76
         </a>
         ], and approximately 15 percent of affected males develop precocious puberty, which is due to overproduction of testosterone [
         <a href="#rid60">
          60,62
         </a>
         ].
        </p>
        <p>
         Due to the rarity of this disorder in males, information about treatment outcomes is very limited. A few case reports describe successful treatment of these individuals with an antiandrogen in combination with an aromatase inhibitor to prevent conversion to estradiol and subsequent bone age advancement, similar to the regimen used for familial male-limited precocious puberty described below [
         <a href="#rid62">
          62,63,75,77
         </a>
         ]. (See
         <a class="local">
          'Familial male-limited precocious puberty'
         </a>
         below.)
        </p>
        <p>
         The pathogenesis and presentation of MAS are outlined in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'McCune-Albright syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23809063">
         <span class="h2">
          Familial male-limited precocious puberty
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial male-limited precocious puberty, also called familial gonadotropin-independent precocious puberty or familial testotoxicosis, is a rare genetic condition in males that is caused by an activating mutation in the gene encoding the luteinizing hormone (LH) receptor, which results in premature Leydig cell maturation and testosterone secretion.
        </p>
        <p>
         The disorder is treated with a combination of an antiandrogen (an androgen receptor antagonist; eg,
         <a class="drug drug_pediatric" data-topicid="12803" href="/z/d/drug information/12803.html" rel="external">
          spironolactone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          bicalutamide
         </a>
         ) and an aromatase inhibitor, eg
         <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">
          anastrozole
         </a>
         , which inhibits the conversion of testosterone to estradiol, thereby slowing further epiphyseal maturation (
         <a class="graphic graphic_figure graphicRef62460" href="/z/d/graphic/62460.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid78">
          78-80
         </a>
         ]. The resulting decrease in sex steroid levels may lead to CPP. If so, CPP is treated with a GnRH agonist [
         <a href="#rid61">
          61,75
         </a>
         ].
        </p>
        <p>
         The optimal treatment regimen has not been established, because data are limited to small case series and direct comparisons are lacking. Based upon available published data, we use the combination of
         <a class="drug drug_pediatric" data-topicid="12803" href="/z/d/drug information/12803.html" rel="external">
          spironolactone
         </a>
         and
         <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">
          anastrozole
         </a>
         (testolactone is no longer available). Preliminary results of such combination therapy are promising. Results of published case series are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the largest case series to date, 25 subjects with familial male-limited precocious puberty were treated with a combination of
         <a class="drug drug_pediatric" data-topicid="12803" href="/z/d/drug information/12803.html" rel="external">
          spironolactone
         </a>
         and either testolactone or
         <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">
          anastrozole
         </a>
         (once testolactone was no longer available) and followed to adult height. GnRH agonist therapy was introduced if there was evidence of secondary activation of CPP. This treatment regimen resulted in an increased adult height compared with the predicted adult height at the time of initial assessment of 12.4 cm (1.3 standard deviations) [
         <a href="#rid81">
          81
         </a>
         ] and is consistent with initial findings from a smaller case series published by the same investigators [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a case report of two males with familial male-limited precocious puberty, a regimen of
         <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">
          bicalutamide
         </a>
         and
         <a class="drug drug_general" data-topicid="8780" href="/z/d/drug information/8780.html" rel="external">
          anastrozole
         </a>
         was effective in reducing height velocity and decreasing secondary sexual characteristics without serious adverse effects [
         <a href="#rid82">
          82
         </a>
         ]. In an open-label study in 14 males, the same combination effectively reduced height velocity and bone age maturation; gynecomastia and breast tenderness were the most common side effects [
         <a href="#rid83">
          83
         </a>
         ]. Further data on final adult height and safety are needed for this combination of medications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other regimens have included
         <a class="drug drug_pediatric" data-topicid="13401" href="/z/d/drug information/13401.html" rel="external">
          ketoconazole
         </a>
         , an inhibitor of steroid synthesis, which was effective in two small series [
         <a href="#rid84">
          84,85
         </a>
         ] but may cause hepatotoxicity and adrenal insufficiency [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23809070">
         <span class="h1">
          BENIGN OR NONPROGRESSIVE PUBERTAL VARIANTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients presenting with idiopathic isolated premature thelarche or premature adrenarche, clinical reexamination and follow-up are important to confirm the diagnosis because some patients with an initial presentation that is consistent with a benign pubertal variant will turn out to have a progressive disorder such as central precocious puberty (CPP) or peripheral precocity. If reexamination confirms lack of rapid progression in secondary sexual characteristics, these children need no therapy and can be discharged from clinical care. Similarly, intermittent or slowly progressive precocious puberty does not warrant therapy. (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Types of benign or nonprogressive pubertal variants'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2414498425">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117619.html" rel="external">
          "Society guideline links: Normal puberty and puberty-related disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11140954">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16739.html" rel="external">
          "Patient education: Early puberty (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23809077">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Types of precocious puberty
         </strong>
         – The etiology of precocious puberty is classified by the underlying pathogenesis into three categories: central precocious puberty (CPP; also known as gonadotropin-dependent precocious puberty or true precocious puberty), peripheral precocity (also known as gonadotropin-independent precocious puberty or peripheral precocious puberty), and benign or nonprogressive pubertal variants (
         <a class="graphic graphic_table graphicRef52565 graphicRef59268 graphicRef72054" href="/z/d/graphic/52565.html" rel="external">
          table 1A-C
         </a>
         ). (See
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CPP
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Decision to treat
         </strong>
         – The primary goal of treatment for CPP is to allow a child to grow to a normal adult height; relieving psychosocial distress, if present, is an additional goal. For patients with CPP, the decision about whether to treat largely depends on the age of onset of CPP, the rate of sexual maturation, and the estimated adult height as determined by the rate of bone age advancement (
         <a class="graphic graphic_table graphicRef72017" href="/z/d/graphic/72017.html" rel="external">
          table 2
         </a>
         ). In general, treatment is most likely to be beneficial for children who are younger, have rapid pubertal progression, and shorter predicted adult height. Children with slowly progressive forms of CPP do not require treatment, because they reach their height potential without treatment. (See
         <a class="local">
          'Decision to treat'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gonadotropin-releasing hormone (GnRH) agonist therapy
         </strong>
         – If treatment for CPP is indicated, GnRH agonists are used. Clinically significant increments in height potential are achieved with a variety of GnRH agonists, and outcome data are insufficient to recommend one form over another; several preparations are listed in the table (
         <a class="graphic graphic_table graphicRef72979" href="/z/d/graphic/72979.html" rel="external">
          table 3
         </a>
         ). The choice of GnRH agonist formulation depends on patient and clinician preference and local insurance and regulatory approvals; in our practice, we use either the one-month or three-month preparation of
         <a class="drug drug_pediatric" data-topicid="12545" href="/z/d/drug information/12545.html" rel="external">
          leuprolide
         </a>
         depot given intramuscularly. (See
         <a class="local">
          'Formulations and dosing'
         </a>
         above and
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monitoring
         </strong>
         – During treatment with a GnRH agonist, patients should be monitored periodically for pubertal development, height velocity, and bone age to determine whether the dose and interval are adequate. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral precocity
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Causes
         </strong>
         – Peripheral precocity is caused by excess secretion of sex hormones either from the gonads or adrenal glands, by exogenous sources of sex steroids, or driven by ectopic human chorionic gonadotropin (hCG) production by a germ cell tumor; in these cases, the precocity is GnRH independent. Causes of peripheral precocity are listed in the table (
         <a class="graphic graphic_table graphicRef59268" href="/z/d/graphic/59268.html" rel="external">
          table 1B
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">
          "Definition, etiology, and evaluation of precocious puberty", section on 'Causes of peripheral precocity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management
         </strong>
         – Treatment for peripheral precocity is directed at blocking the production of and/or response to the excess sex steroids; these patients do not respond to GnRH agonist therapy, unless they have developed secondary CPP (
         <a class="graphic graphic_figure graphicRef62460" href="/z/d/graphic/62460.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="local">
          'Treatment for peripheral precocity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benign or nonprogressive variants
         </strong>
         – Benign or nonprogressive pubertal variants include isolated breast development (premature thelarche) or isolated characteristics such as pubic hair development mediated by androgens produced by early maturation of the adrenal glands (premature adrenarche). Either of these patterns usually is a variant of normal puberty and requires no intervention. However, clinical reexamination and follow-up are important to confirm the diagnosis because some patients with an initial presentation that is consistent with a benign pubertal variant will turn out to have a progressive disorder. (See
         <a class="local">
          'Benign or nonprogressive pubertal variants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         <strong>
          ACKNOWLEDGMENT
         </strong>
         — The UpToDate editorial staff acknowledges Paul Saenger, MD, MACE, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000; 13 Suppl 1:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev 1986; 7:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowley WF Jr, Comite F, Vale W, et al. Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981; 52:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahachoklertwattana P, Kaplan SL, Grumbach MM. The luteinizing hormone-releasing hormone-secreting hypothalamic hamartoma is a congenital malformation: natural history. J Clin Endocrinol Metab 1993; 77:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Striano S, Santulli L, Ianniciello M, et al. The gelastic seizures-hypothalamic hamartoma syndrome: facts, hypotheses, and perspectives. Epilepsy Behav 2012; 24:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carel JC, Léger J. Clinical practice. Precocious puberty. N Engl J Med 2008; 358:2366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009; 123:e752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangalore Krishna K, Fuqua JS, Rogol AD, et al. Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium. Horm Res Paediatr 2019; 91:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999; 84:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontoura M, Brauner R, Prevot C, Rappaport R. Precocious puberty in girls: early diagnosis of a slowly progressing variant. Arch Dis Child 1989; 64:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazar L, Pertzelan A, Weintrob N, et al. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab 2001; 86:4127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franzini IA, Yamamoto FM, Bolfi F, et al. GnRH analog is ineffective in increasing adult height in girls with puberty onset after 7 years of age: a systematic review and meta-analysis. Eur J Endocrinol 2018; 179:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vargas Trujillo M, Dragnic S, Aldridge P, Klein KO. Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years. J Pediatr Endocrinol Metab 2021; 34:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007; 92:3483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mul D, Bertelloni S, Carel JC, et al. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res 2002; 58:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplowitz P, Bloch C, Section on Endocrinology, American Academy of Pediatrics. Evaluation and Referral of Children With Signs of Early Puberty. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bar A, Linder B, Sobel EH, et al. Bayley-Pinneau method of height prediction in girls with central precocious puberty: correlation with adult height. J Pediatr 1995; 126:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoelwer MJ, Donahue KL, Bryk K, et al. Psychological assessment of mothers and their daughters at the time of diagnosis of precocious puberty. Int J Pediatr Endocrinol 2015; 2015:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menk TAS, Inácio M, Macedo DB, et al. Assessment of stress levels in girls with central precocious puberty before and during long-acting gonadotropin-releasing hormone agonist treatment: a pilot study. J Pediatr Endocrinol Metab 2017; 30:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoelwer MJ, Donahue KL, Didrick P, Eugster EA. One-Year Follow-Up of Girls with Precocious Puberty and Their Mothers: Do Psychological Assessments Change over Time or with Treatment? Horm Res Paediatr 2017; 88:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkham YA, Allen L, Kives S, et al. Trends in menstrual concerns and suppression in adolescents with developmental disabilities. J Adolesc Health 2013; 53:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr 2011; 159:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee PA, Klein K, Mauras N, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab 2012; 97:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carel JC, Blumberg J, Seymour C, et al. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006; 154:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein K, Yang J, Aisenberg J, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab 2016; 29:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007; 92:1697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahhal S, Clarke WL, Kletter GB, et al. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol 2009; 2009:812517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverman LA, Neely EK, Kletter GB, et al. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial. J Clin Endocrinol Metab 2015; 100:2354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis KA, Goldyn AK, West KW, Eugster EA. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. J Pediatr 2013; 163:1214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher MM, Lemay D, Eugster EA. Resumption of puberty in girls and boys following removal of the histrelin implant. J Pediatr 2014; 164:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertelloni S, Massart F, Einaudi S, et al. Central Precocious Puberty: Adult Height in Girls Treated with Quarterly or Monthly Gonadotropin-Releasing Hormone Analog Triptorelin. Horm Res Paediatr 2015; 84:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein KO, Freire A, Gryngarten MG, et al. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinrichs C, Craen M, Vanderschueren-Lodeweyckx M, et al. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology. Acta Paediatr 1994; 83:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 2002; 109:E30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demirbilek H, Alikasifoglu A, Gonc NE, et al. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection. Clin Endocrinol (Oxf) 2012; 76:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wierman ME, Beardsworth DE, Crawford JD, et al. Adrenarche and skeletal maturation during luteinizing hormone releasing hormone analogue suppression of gonadarche. J Clin Invest 1986; 77:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka T, Niimi H, Matsuo N, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab 2005; 90:1371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson SR, Nolan RC, Grant MT, et al. Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty. J Paediatr Child Health 2012; 48:E136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis JS, Alkhoury F, Burnweit C. Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty. J Pediatr Surg 2014; 49:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen M, Eugster EA. Central Precocious Puberty: Update on Diagnosis and Treatment. Paediatr Drugs 2015; 17:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirkgoz T, Karakoc-Aydiner E, Bugrul F, et al. Management of Systemic Hypersensitivity Reactions to Gonadotropin-Releasing Hormone Analogues during Treatment of Central Precocious Puberty. Horm Res Paediatr 2020; 93:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omar AA, Nyaga G, Mungai LNW. Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty. Int J Pediatr Endocrinol 2020; 2020:22.
          </a>
         </li>
         <li class="breakAll">
          Manufacturer's prescribing information for FENSOLVI, 4/2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213150s002lbl.pdf (Accessed on April 28, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gül Ü, Kaçar Bayram A, Kendirci M, et al. Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment. J Clin Res Pediatr Endocrinol 2016; 8:365.
          </a>
         </li>
         <li class="breakAll">
          Pediatric Endocrine Society. Risk of prolonged QT interval with gonadotropin releasing hormone agonists. 2017. Available at: https://www.pedsendo.org/education_training/healthcare_providers/consensus_statements/assets/Risk_of_Prolonged_QT_Interval_with_GnRHa.pdf (Accessed on November 28, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gagliano-Jucá T, Travison TG, Kantoff PW, et al. Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. J Endocr Soc 2018; 2:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thornton P, Silverman LA, Geffner ME, et al. Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty. Pediatr Endocrinol Rev 2014; 11:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazar L, Meyerovitch J, de Vries L, et al. Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades. Clin Endocrinol (Oxf) 2014; 80:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neely EK, Lee PA, Bloch CA, et al. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010; 2010:398639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassio A, Bal MO, Orsini LF, et al. Reproductive outcome in patients treated and not treated for idiopathic early puberty: long-term results of a randomized trial in adults. J Pediatr 2006; 149:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertelloni S, Baroncelli GI, Ferdeghini M, et al. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr 2000; 159:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmert MR, Mansfield MJ, Crowley WF Jr, et al. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999; 84:4480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazar L, Lebenthal Y, Yackobovitch-Gavan M, et al. Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades. J Clin Endocrinol Metab 2015; 100:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park HK, Lee HS, Ko JH, et al. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin Endocrinol (Oxf) 2012; 77:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquino AM, Pucarelli I, Accardo F, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008; 93:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franceschi R, Gaudino R, Marcolongo A, et al. Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. Fertil Steril 2010; 93:1185.
          </a>
         </li>
         <li class="breakAll">
          Lee PA, Kerrigan JR. Precocious Puberty. In: Pediatric Endocrinology, Pescovitz OH, Eugster EA (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.329.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papanikolaou A, Michala L. Autonomous Ovarian Cysts in Prepubertal Girls. How Aggressive Should We Be? A Review of the Literature. J Pediatr Adolesc Gynecol 2015; 28:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Sousa G, Wunsch R, Andler W. Precocious pseudopuberty due to autonomous ovarian cysts: a report of ten cases and long-term follow-up. Hormones (Athens) 2008; 7:170.
          </a>
         </li>
         <li class="breakAll">
          Boyce AM, Florenzano P, de Castro LF, Collins MT.. GeneReviews®, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A. (Eds), University of Washington, Seattle, Seattle (WA) 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland FJ, Kirsch SE, Selby R. Gonadotropin-independent precocious puberty ("testotoxicosis"): influence of maturational status on response to ketoconazole. J Clin Endocrinol Metab 1987; 64:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyce AM, Chong WH, Shawker TH, et al. Characterization and management of testicular pathology in McCune-Albright syndrome. J Clin Endocrinol Metab 2012; 97:E1782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javaid MK, Boyce A, Appelman-Dijkstra N, et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet J Rare Dis 2019; 14:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eugster EA. Peripheral precocious puberty: causes and current management. Horm Res 2009; 71 Suppl 1:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feuillan P, Calis K, Hill S, et al. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab 2007; 92:2100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estrada A, Boyce AM, Brillante BA, et al. Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome. Eur J Endocrinol 2016; 175:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feuillan PP, Foster CM, Pescovitz OH, et al. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med 1986; 315:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feuillan PP, Jones J, Cutler GB Jr. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993; 77:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nunez SB, Calis K, Cutler GB Jr, et al. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 2003; 88:5730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shulman DI, Francis GL, Palmert MR, et al. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics 2008; 121:e975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mieszczak J, Lowe ES, Plourde P, Eugster EA. The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome. J Clin Endocrinol Metab 2008; 93:2751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eugster EA, Rubin SD, Reiter EO, et al. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 2003; 143:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de G Buff Passone C, Kuperman H, Cabral de Menezes-Filho H, et al. Tamoxifen Improves Final Height Prediction in Girls with McCune-Albright Syndrome: A Long Follow-Up. Horm Res Paediatr 2015; 84:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sims EK, Garnett S, Guzman F, et al. Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome. Int J Pediatr Endocrinol 2012; 2012:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddad N, Eugster E. An update on the treatment of precocious puberty in McCune-Albright syndrome and testotoxicosis. J Pediatr Endocrinol Metab 2007; 20:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lumbroso S, Paris F, Sultan C, European Collaborative Study. Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study. J Clin Endocrinol Metab 2004; 89:2107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenz AM, Shulman D, Eugster EA, et al. Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. Pediatrics 2010; 126:e728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland FJ, Fishman L, Bailey JD, Fazekas AT. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Engl J Med 1985; 312:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laue L, Kenigsberg D, Pescovitz OH, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989; 320:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leschek EW, Jones J, Barnes KM, et al. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999; 84:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leschek EW, Flor AC, Bryant JC, et al. Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty. J Pediatr 2017; 190:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreher NC, Pescovitz OH, Delameter P, et al. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr 2006; 149:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiter EO, Mauras N, McCormick K, et al. Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). J Pediatr Endocrinol Metab 2010; 23:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soriano-Guillén L, Lahlou N, Chauvet G, et al. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J Clin Endocrinol Metab 2005; 90:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almeida MQ, Brito VN, Lins TS, et al. Long-term treatment of familial male-limited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole. Clin Endocrinol (Oxf) 2008; 69:93.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Nizoral (ketoconazole): Potentially Fatal Liver Injury, Risk of Drug Interactions and Adrenal Gland Problems. 2013. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm362672.htm?source=govdelivery (Accessed on July 30, 2013).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16318 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10969915" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2937629" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6780592" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8325933" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The luteinizing hormone-releasing hormone-secreting hypothalamic hamartoma is a congenital malformation: natural history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22503469" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The gelastic seizures-hypothalamic hamartoma syndrome: facts, hypotheses, and perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18509122" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clinical practice. Precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19332438" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Consensus statement on the use of gonadotropin-releasing hormone analogs in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31319416" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10022394" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2782932" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Precocious puberty in girls: early diagnosis of a slowly progressing variant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11549638" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30324797" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : GnRH analog is ineffective in increasing adult height in girls with puberty onset after 7 years of age: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33856747" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17579199" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12169774" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26668298" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Evaluation and Referral of Children With Signs of Early Puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7776106" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Bayley-Pinneau method of height prediction in girls with central precocious puberty: correlation with adult height.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25780366" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Psychological assessment of mothers and their daughters at the time of diagnosis of precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28599388" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Assessment of stress levels in girls with central precocious puberty before and during long-acting gonadotropin-releasing hormone agonist treatment: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28926827" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : One-Year Follow-Up of Girls with Precocious Puberty and Their Mothers: Do Psychological Assessments Change over Time or with Treatment?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23763962" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Trends in menstrual concerns and suppression in adolescents with developmental disabilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21798557" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22344198" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16382000" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26887034" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17327379" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19956699" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25803268" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23809043" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24433825" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Resumption of puberty in girls and boys following removal of the histrelin implant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26528763" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Central Precocious Puberty: Adult Height in Girls Treated with Quarterly or Monthly Gonadotropin-Releasing Hormone Analog Triptorelin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32738042" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7919761" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11826240" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21790701" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2935557" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Adrenarche and skeletal maturation during luteinizing hormone releasing hormone analogue suppression of gonadarche.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15598675" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21564386" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24851775" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25911294" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Central Precocious Puberty: Update on Diagnosis and Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31972562" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Management of Systemic Hypersensitivity Reactions to Gonadotropin-Releasing Hormone Analogues during Treatment of Central Precocious Puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33292495" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33292495" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27087351" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27087351" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29761176" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24719967" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Review of outcomes after cessation of gonadotropin-releasing hormone agonist treatment of girls with precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24033561" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21437000" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17011327" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Reproductive outcome in patients treated and not treated for idiopathic early puberty: long-term results of a randomized trial in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10834524" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10599706" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25650898" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22530679" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17940112" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19135667" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19135667" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26228588" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Autonomous Ovarian Cysts in Prepubertal Girls. How Aggressive Should We Be? A Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18477555" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Precocious pseudopuberty due to autonomous ovarian cysts: a report of ten cases and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18477555" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Precocious pseudopuberty due to autonomous ovarian cysts: a report of ten cases and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3539979" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Gonadotropin-independent precocious puberty ("testotoxicosis"): influence of maturational status on response to ketoconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22745241" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Characterization and management of testicular pathology in McCune-Albright syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31196103" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19153509" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Peripheral precocious puberty: causes and current management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17405850" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27562402" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3093862" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8370686" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14671160" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18381525" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18397987" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12915825" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26227563" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Tamoxifen Improves Final Height Prediction in Girls with McCune-Albright Syndrome: A Long Follow-Up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22999294" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17663289" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : An update on the treatment of precocious puberty in McCune-Albright syndrome and testotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15126527" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20713483" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Bicalutamide and third-generation aromatase inhibitors in testotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2984563" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2492636" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Treatment of familial male precocious puberty with spironolactone and testolactone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9920079" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29144249" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16939760" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21158211" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15522928" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18088394" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Long-term treatment of familial male-limited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
